CAJ | 학술논문

探讨槐耳颗粒联合吉非替尼在晚期肺腺癌治疗中的临床应用价值。将患者随机分为治疗组和对照组，治疗组采用口服槐耳颗粒联合吉非替尼，对照组单纯口服吉非替尼。4个疗程后，分别观察两组治疗前后机体免疫状态、瘤体大小、生存质量的变化和药物毒副反应等指标。结果发现两组患者瘤体大小和生存质量差异无统计学意义（P＞0．05），但治疗组和对照组比较 CD8＋明显下降、CD4＋／CD8＋比值上升，差异有统计学意义（P＜0．05），毒副反应方面，恶心呕吐、腹泻等药物不良反应相对较轻，但差异无统计学意义（P＞0．05）。因此，槐耳颗粒可显著提高患者的免疫功能，有较大的临床应用价值，可以与吉非替尼联合治疗晚期肺腺癌患者。
탐토괴이과립연합길비체니재만기폐선암치료중적림상응용개치。장환자수궤분위치료조화대조조，치료조채용구복괴이과립연합길비체니，대조조단순구복길비체니。4개료정후，분별관찰량조치료전후궤체면역상태、류체대소、생존질량적변화화약물독부반응등지표。결과발현량조환자류체대소화생존질량차이무통계학의의（P＞0．05），단치료조화대조조비교 CD8＋명현하강、CD4＋／CD8＋비치상승，차이유통계학의의（P＜0．05），독부반응방면，악심구토、복사등약물불량반응상대교경，단차이무통계학의의（P＞0．05）。인차，괴이과립가현저제고환자적면역공능，유교대적림상응용개치，가이여길비체니연합치료만기폐선암환자。
To investigate the clinical value of Huaier particles combined Gefitinib in advanced lung adenocarcinoma ,50 patients were divided randomly into two groups ,the treatment group (25 cases) and the control group (25 cases) .Huaier particles combined Gefitinib were given in the treatment group ,and Gefitinib was simply given in the control group .The changes of patients'immune status ,tumor size ,quality of life and drug toxicity followed in four courses ,were compared pre - treatment and post - treatment respectively in two groups .The results showed that tumor size and survival quality of the treatment group and the control group after treatment had no significant difference (P> 0 .05) .But after treatment , CD8 + in the treatment group was significantly decreased while the ratio of CD 4 + /CD8 + increased significantly ( P <0 .05) .Compared with the control group after treatment ,CD8 + and the ratio of CD4 + /CD8 + in the treatment group after treatment were different significantly ( P < 0 .05 ) . Nausea ,vomiting ,diarrhea and other adverse drug reactions were relatively mild in the treatment group ,but there were no significant difference (P> 0 .05) .We believe Huaier particles can significantly improve immune function in patients with greater clinical value and can be combined with gefitinib in patients with advanced lung cancer .